Calidi Biotherapeutics, Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Calidi Biotherapeutics, Inc. (CLDI) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$157.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$3.00K.
- Calidi Biotherapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$32.00K.
- Calidi Biotherapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$46.00K.
- Calidi Biotherapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-03-31 was -$76.00K.
- Calidi Biotherapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2025 was -$157.00K.
- Calidi Biotherapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$66.00K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$35.00K derived: sum of 2 quarters · filed 2026-03-27 | -$81.00K derived: sum of 3 quarters · filed 2026-08-13 | -$157.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | -$32.00K 10-Q · filed 2025-11-13 | -$78.00K derived: sum of 2 quarters · filed 2026-08-13 | -$154.00K 10-Q · filed 2025-11-13 | -$205.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$46.00K 10-Q · filed 2026-08-13 | -$122.00K 10-Q · filed 2026-08-13 | -$173.00K derived: sum of 3 quarters · filed 2026-08-13 | -$188.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$76.00K 10-Q · filed 2026-05-14 | -$127.00K derived: sum of 2 quarters · filed 2026-05-14 | -$142.00K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$66.00K derived: sum of 2 quarters · filed 2026-03-27 | -$66.00K 10-K · filed 2026-03-27 | |
| 2024-09-30 | -$15.00K 10-Q · filed 2025-11-13 | -$15.00K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |